ART gains European clearance for SoftScan device
7 March 2007
Montreal, Canada. ART Advanced Research Technologies Inc.
(TSX: ARA), a Canadian producer of optical molecular imaging products, has
received the CE certificate for its SoftScan optical breast imaging device,
allowing it to be sold throughout the European market.
Obtaining the CE
marking enables ART to sell its SoftScan device in all 25 member states of
the European Union (EU), as well as in Norway, Iceland, Liechtenstein and
Turkey, without having to undergo country specific certifications.
SoftScan is a non-invasive and painless optical imaging technology, which
enables the characterization of breast tumours by clinicians as benign or
malignant, without exposing the patients to ionizing radiation.
the CE marking represents an important commercial milestone for ART and
opens up an important market for our SoftScan device,” said Sébastien
Gignac, President and CEO of ART. “We are now one critical step closer to
commercialization of SoftScan in Europe.”
Joseph Kozikowski, M.D., ART’s
Chief Medical Officer, added: "SoftScan has been received with great
interest in Europe, especially in the area of treatment monitoring. I expect
this CE marking to help doctors and hospitals across Europe to improve
patient care with SoftScan breast imaging."